NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analysesMontserrat García‐Closas, Nathaniel Rothman, Stephen J. Chanock et al.|The Lancet|2005Cited by 631
Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) ConsortiumMichael Goggins, Marco J. Bruno, Kasper A. Overbeek et al.|Gut|2019Cited by 620
Telomerase Reverse Transcriptase Promoter Mutations in Bladder Cancer: High Frequency Across Stages, Detection in Urine, and Lack of Association with OutcomeYves Allory, Francisco X. Real, Willemien Beukers et al.|European Urology|2013Cited by 289
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)Enrique Grande, Rocio García‐Carbonero, Jaume Capdevila et al.|Annals of Oncology|2015Cited by 157
Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) ConsortiumTamas A. Gonda, George Zogopoulos, Jessica N. Everett et al.|Gastroenterology|2021Cited by 42